
A18i Consulting LLC
2331 University Blvd
Houston, TX 77005, United States
Science-driven healthcare expertise
Collaboration with leading institutions
Assay development and commercialisation
Co-Founder
Friedrich previously worked as a management consultant (McKinsey & Company), investment banker (Morgan Stanley), private equity analyst (Partners Group) and entrepreneur in the health care industry. He holds an MPH in Epidemiology from Yale University and an MSc in Management from the London School of Economics.
Vice President- Research
Emmanuella holds a BA from Harvard University, a MA from Cambridge University and a MD-PhD from Yale University. Her research focusses on the impact of structural racism on health. At A18i, Emmanuella heads the research department. In 2022, she was included into the Forbes 30 under 30 Healthcare List.
Vice President - Translational Science
Jeff holds a PhD in Biomedical Sciences from Baylor College of Medicine and BSc in Biochemistry and Molecular Biology from Illinois State University. He previously worked as Discovery Scientist at LakePharma and co-founded RioRaiz, a nonprofit therapy discovery organisation.
The A18i team founded NeraCare GmbH in 2017 and have been leading the company’s strategy and operations since. Under A18i's leadership, NeraCare raised more than $20 million in venture capital funding led by MIG Capital AG, also a founding investor of German biotech giant BioNTech. The company also set up the NivoMela trial, the first clinical trial in oncology to select patients for adjuvant treatment based on individualized risk for relapse. In the news: December 2024: Akoya Biosciences and NeraCare enter into exclusive global license agreement September 2024: Interview with A18i founders Friedrich and Daniel on Immunoprint
A18i Consulting LLC
2331 University Blvd
Houston, TX 77005, United States